MX362532B - Derivados de 1,7-naftiridina. - Google Patents

Derivados de 1,7-naftiridina.

Info

Publication number
MX362532B
MX362532B MX2016000895A MX2016000895A MX362532B MX 362532 B MX362532 B MX 362532B MX 2016000895 A MX2016000895 A MX 2016000895A MX 2016000895 A MX2016000895 A MX 2016000895A MX 362532 B MX362532 B MX 362532B
Authority
MX
Mexico
Prior art keywords
lower alkyl
halogen
disease
hydrogen
substituted
Prior art date
Application number
MX2016000895A
Other languages
English (en)
Other versions
MX2016000895A (es
Inventor
Wichmann Juergen
Peters Jens-Uwe
M Ceccarelli Simona
Jagasia Ravi
Jakob-Roetne Roland
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016000895A publication Critical patent/MX2016000895A/es
Publication of MX362532B publication Critical patent/MX362532B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención está relacionada con los compuestos de fórmula general (I) en los que R1 es fenilo o piridinilo, que está opcionalmente sustituido por uno, dos o tres sustituyentes, seleccionados entre halógeno, alquilo inferior sustituido por halógeno, alcoxi inferior, alcoxi inferior sustituido por halógeno, ciano o S(O)2-alquilo inferior, o es morfolinilo, dihidropiranilo o piperidinilo, en el qué piperidinilo está opcionalmente sustituido por halógeno, o es C(O)O-alquilo inferior; R2es hidrógeno; R3 es hidrógeno, alquilo inferior sustituido por halógeno, -(CH2)n- S(O)2-alquilo inferior, -(CH2)n-cicloalquilo o -(CH2)n-alcoxi inferior; R4 es hidrógeno o alquilo inferior; n es 0, 1 o 2; o una sal de adición ácida farmacéuticamente aceptable, a una mezcla racémica o a sus correspondientes enantiómeros y/o isómeros ópticos de los mismos. Los compuestos pueden usarse para el tratamiento de esquizofrenia, trastorno de la personalidad obsesivo-compulsivo, depresión mayor, trastornos bipolares, trastornos de ansiedad, envejecimiento normal, epilepsia, degeneración retinal, daño cerebral traumático, daño en la médula espinal, trastorno de estrés postraumático, trastorno de pánico, enfermedad de Parkinson, demencia, enfermedad de Alzheimer, deterioro cognitivo, disfunción cognitiva inducida por la quimioterapia ("quimiocerebral"), síndrome de Down, trastornos de espectro autista, hipoacusia, tinnitus, ataxia espinocerebelar, esclerosis lateral amiotrófica, esclerosis múltiple, enfermedad de Huntington, accidente cerebrovascular y alteraciones debidas a la terapia de radiación, estrés crónico, neuropatía óptica o degeneración macular, o abuso de drogas neuroactivas, seleccionadas de entre alcohol, opiáceos, metanfetamina, fenciclidina y cocaína.
MX2016000895A 2013-07-29 2014-07-28 Derivados de 1,7-naftiridina. MX362532B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13178373 2013-07-29
PCT/EP2014/066123 WO2015014768A1 (en) 2013-07-29 2014-07-28 1,7-naphthyridine derivatives

Publications (2)

Publication Number Publication Date
MX2016000895A MX2016000895A (es) 2016-05-05
MX362532B true MX362532B (es) 2019-01-23

Family

ID=48874925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000895A MX362532B (es) 2013-07-29 2014-07-28 Derivados de 1,7-naftiridina.

Country Status (13)

Country Link
US (1) US9688675B2 (es)
EP (1) EP3027597B1 (es)
JP (1) JP6130071B2 (es)
KR (1) KR101781762B1 (es)
CN (1) CN105473568B (es)
AR (1) AR097088A1 (es)
CA (1) CA2917602A1 (es)
ES (1) ES2630317T3 (es)
HK (1) HK1216749A1 (es)
MX (1) MX362532B (es)
RU (1) RU2669943C2 (es)
TW (1) TWI529171B (es)
WO (1) WO2015014768A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101861937B1 (ko) * 2013-11-12 2018-05-28 에프. 호프만-라 로슈 아게 신경변성 장애의 치료를 위한 신경성 제제로서의 피라진-2-카복스아마이드
EP3889146A1 (en) * 2015-12-17 2021-10-06 Merck Patent GmbH Polyheterocyclic tlr7/8 antagonists and their uses for treating immune disorders
CN106008487B (zh) 2015-12-31 2019-08-09 北京理工大学 一种二苯乙烯类衍生物及其制备方法
CA3068350A1 (en) 2017-06-30 2019-01-03 Bayer Animal Health Gmbh New azaquinoline derivatives
RU2739489C2 (ru) * 2018-03-06 2020-12-24 Закрытое Акционерное Общество "Биокад" Новые гетероциклические соединения как ингибиторы CDK8/19
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
RU2761824C2 (ru) 2018-08-03 2021-12-13 Закрытое Акционерное Общество "Биокад" Ингибиторы CDK8/19

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2354627T3 (es) * 2005-10-05 2011-03-16 F. Hoffmann-La Roche Ag Derivados de naftiridina.
US20080242694A1 (en) * 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
WO2008046072A2 (en) * 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
ES2474147T3 (es) * 2008-05-30 2014-07-08 Amgen, Inc Inhibidores de PI3 cinasa
MX2011009213A (es) * 2009-03-02 2011-12-14 Sirtris Pharmaceuticals Inc Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
SG182803A1 (en) * 2010-02-05 2012-09-27 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
KR20150085538A (ko) 2012-11-20 2015-07-23 에프. 호프만-라 로슈 아게 치환된 1,6-나프티리딘

Also Published As

Publication number Publication date
WO2015014768A1 (en) 2015-02-05
RU2016104890A (ru) 2017-08-31
CN105473568A (zh) 2016-04-06
CN105473568B (zh) 2018-02-13
AR097088A1 (es) 2016-02-17
HK1216749A1 (zh) 2016-12-02
TW201516044A (zh) 2015-05-01
MX2016000895A (es) 2016-05-05
JP6130071B2 (ja) 2017-05-17
KR20160027068A (ko) 2016-03-09
EP3027597B1 (en) 2017-05-03
TWI529171B (zh) 2016-04-11
US9688675B2 (en) 2017-06-27
CA2917602A1 (en) 2015-02-05
ES2630317T3 (es) 2017-08-21
KR101781762B1 (ko) 2017-09-25
US20160137643A1 (en) 2016-05-19
RU2669943C2 (ru) 2018-10-17
EP3027597A1 (en) 2016-06-08
RU2016104890A3 (es) 2018-05-15
JP2016525142A (ja) 2016-08-22

Similar Documents

Publication Publication Date Title
MX362532B (es) Derivados de 1,7-naftiridina.
MX2016008842A (es) Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
MX2015015052A (es) Derivados de isoquinolina que estimulan la neurogenesis.
MX2015006364A (es) 1,6-naftiridinas sustituidas.
PH12016502231A1 (en) Indolin-2-one or pyrrolo-pyridin-2-one derivatives
MX2016008983A (es) Peliculas termocontraibles de barrera de multicapa pvdc.
MX370661B (es) Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona.
AR093576A1 (es) Derivados heterociclicos sustituidos
MX2015017343A (es) Derivados de pirrolopiridina o pirazolopiridina.
MX2016008536A (es) Derivados de fluoro-naftilo.
RU2015112914A (ru) Бензимидазолы в качестве активных агентов для центральной нервной системы
AR106588A1 (es) Derivados de indolin-2-ona para el tratamiento de enfermedades del snc
PH12016500605A1 (en) Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
PH12015500059A1 (en) Pieprazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
BR112015008200A2 (pt) derivados de imidazopiridina
MX2015000629A (es) Moduladores de benzisoxasol de neurogenesis.
MX2015013915A (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona.
MX2016001528A (es) Derivados de indol-carboxamida.
TH165816B (th) ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท
TH165816A (th) ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท

Legal Events

Date Code Title Description
FG Grant or registration